Clinical Trial

New Biomarkers of Bone Mineral Metabolism as Cardiovascular Risk Factors in Chronic Kidney Disease Patients

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 4, 2022 (before its estimated March 2024 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the relationships between bone mineral metabolism markers (osteoprotegerin, fibroblast growth factor 23) at inclusion and the occurence of cardiovascular events during a 7 year follow-up.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2016-06-17; most recent amendment 2021-12-31.
Trial Details
NCT Number NCT02808572
Lead Sponsor University Hospital, Montpellier
Conditions Chronic Kidney Disease
Enrollment 250 participants
Start Date 2013-03-12
Primary Completion 2024-03 (estimated)
Study Completion 2031-06 (estimated)
Updated on ClinicalTrials.gov 2022-01-04